Novavax, Inc. (BMV:NVAX)

Market Cap	19.60B
Revenue (ttm)	19.53B
Net Income (ttm)	6.27B
Shares Out	n/a
EPS (ttm)	37.98
PE Ratio	3.13
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	411
Average Volume	922
Open	120.51
Previous Close	122.00
Day's Range	119.50 - 120.52
52-Week Range	106.50 - 231.28
Beta	n/a
RSI	43.23
Earnings Date	Feb 26, 2026

About Novavax

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 952
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: NVAX

Financial Performance

In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.

Financial numbers in USD